Overview
The Retatrutide 60mg vial provides the triple GLP-1/GIP/glucagon receptor agonist at Nova Biolabs' best value per milligram. As one of the most studied next-generation peptide compounds in current research, Retatrutide's triple receptor mechanism continues to generate significant scientific interest globally.
Held in UK domestic stock and dispatched with fast, discreet packaging.
Key Research Areas
Extended Triple-Receptor Studies
The 60mg vial is ideal for research programmes requiring sustained access to the triple-agonist compound over multiple experimental runs.
GLP-1, GIP and Glucagon Receptor Co-Activation
Studying the simultaneous activation of all three receptors and their downstream intracellular signalling pathways is a key focus of current metabolic research.
Hepatic Glucose Research
The glucagon receptor component of Retatrutide is particularly relevant to research examining hepatic glucose output, glycogenolysis, and gluconeogenesis signalling.
Adipose and Thermogenesis Research
Investigated in fat cell models for its interactions with adipogenesis signalling and thermogenic pathway activation.
Product Specifications
| Format | Lyophilised powder |
| Quantity | 60mg per vial |
| Grade | Research Grade |
| Storage | Refrigerate at 2–8°C. Stable 24 months lyophilised. |
| Origin | UK domestic stock |
| Research use | In vitro / laboratory use only |